Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Inhibition of phospholipase A2 (PLA2) activity by nifedipine and nisoldipine is independent of their calcium-channel-blocking activity

  • 39 Accesses

  • 24 Citations

Abstract

The effects of several calcium antagonists on phospholipase A2 (PLA2) activity were examined. Nifedipine and nisoldipine inhibited a cell-free preparation of PLA2 in a dose-dependent manner with maximal inhibition of 71–77% observed at 100μM. More potent or equipotent dihydropyridine calcium antagonists such as nitrendipine and felodipine did not inhibit PLA2 activity. In addition, nondihydropyridine calcium antagonists such as diltiazem, verapamil, and cinnarazine failed to reduce PLA2 activity markedly. Nifedipine and nisoldipine also reduced PLA2 activity in intact mouse peritoneal macrophages where PLA2 activity was monitored by free [14C]arachidonic acid release from [14C]arachidonic acid-prelabeled cells. When levels of PGE2 and LTC4 were measured by radioimmunoassay, it was found that the synthesis of these two metabolites was concomitantly inhibited by nifedipine and nisoldipine. In vivo, nifedipine and nisoldipine inhibited tetradecanoylphorbol acetate (TPA) induced ear edema. UV irradiation of nifedipine and nisoldipine (which destroys the slow caicium-channel-blocking activity of these compounds) did not result in a loss of PLA2 inhibitory activity. In fact, in both instances the UV-irradiated forms of nifedipine and nisoldipine were slightly more potent PLA2 inhibitors than the parent compound alone. We therefore conclude that the ability of nifedipine and nisoldipine to inhibit PLA2 was direct and unrelated to their actions on slow calcium channels.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Janis, R. A., andA. Scriabine. 1985. Sites of action of Ca2 channel inhibitors.Biochem. Pharmacol. 33:3499–3506.

  2. 2.

    Elferink, J. G. R. 1982. Interference of the calcium antagonists verapamil and nifedipine with lysosomal enzyme release from rabbit polymorphonuclear leukocytes.Arzneim.-Forsch/ Drug Res. 32:1417–1420.

  3. 3.

    Simchowitz, L., andI. Spilberg. 1979. Generation of superoxide radicals by human peripheral neutrophils activated by chemotatic factor. Evidence for the role of calcium.J. Lab. Clin. Med. 93:583–593.

  4. 4.

    Stocker, R., andC. Richter. 1982. Involvement of calcium, calmodulin and phospholipase A in the alteration of membrane dynamics and superoxide production of human neutrophils stimulated by phorbol myristate acetate.FEBS Lett. 147:243–246.

  5. 5.

    Ikeda, Y., M. Kikuchi, K. Toyama, K. Watanabe, andY. Ando. 1981. Effects by nifedipine on platelet function in vivo and in vitro.Thromb. Haemostas. 45:158–164.

  6. 6.

    Honn, K. V., J. M. Onada, K. Pampalona, M. Battaglia, C. Neagos, J. D. Taylor, C. A. Diglios, andB. F. Sloane. 1985. Inhibition by dihydropyridine class calcium-channel blockers of tumor cell-platelet-endothelial cell interactions in vitro and metastasis in vivo,Biochem. Pharmacol. 34:235–241.

  7. 7.

    Crutchley, D. J., J. W. Ryan, U. S. Ryan, andG. H. Fisher. 1983. Bradykinin-induced release of prostacyclin and thromboxanes from bovine pulmonary artery endothelial cells.Biochem. Biophys. Acta 751:99–107.

  8. 8.

    Davi, G., S. Novo, M. Fiore, A. Fodera, A. Kattina, A. Mazzola, andA. Strano. 1982. Effects by nifedipine on thromboxane synthesis in vitro and in vivo.Thromb. Res. 28:837–842.

  9. 9.

    Mehta, J. L. 1985. Influence of calcium channel blockers on platelet function and arachidonic acid metabolism.Am. J. Cardiol. 55:158B-164B.

  10. 10.

    Jouvin-Marche, E., J. Cerrina, E. Coeffier, P. Duroux, andJ. Benveniste. 1983. Effect of the Ca2 antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slowreacting substance, andβ-glucuronidase from human neutrophils.Eut. J. Pharmacol. 89:19–26.

  11. 11.

    Levine, L. 1983. Inhibition of the A-23187-stimulated leukotriene and prostaglandin biosynthesis of rat basophil leukemia (RBL-1) cells by nonsteroidal antiinflammatory drugs, antioxidants, and calcium channel blockers.Biochem. Pharmacol. 32:3023–3026.

  12. 12.

    Damiano, M. A., andE. J. Barbieri. 1985. The release of slow-reacting substance of anaphylaxis from guinea pig lung: Effects of calcium antagonists.Can. J. Physiol. Pharmacol. 63:23–29.

  13. 13.

    Lee, V. Y., J. M. Hughes, J. P. Seale, andD. M. Temple. 1983. Verapamil inhibits mediator release from human lung in vitro.Thorax 38:386–387.

  14. 14.

    Wightman, P. D., M. E. Dahlgren, andR. J. Bonney. 1982. Protein kinase activation of phospholipase A2 in sonicates of mouse peritoneal macrophages.J. Biol. Chem. 257:6650–6652.

  15. 15.

    Chang, J., E. Blazek, A. F. Kreft, andA. J. Lewis. 1985. Inhibition of platelet and neutrophil phospholipase A2 by hydroxyeicosatetraenoic acids (HETEs).Biochem. Pharmacol. 34:1571–1575.

  16. 16.

    Chang, J., F. Wigley, andD. Newcombe. 1980. Neutral protease activation of peritoneal macrophage prostaglandin synthesis.Proc. Natl. Acad. Sci. U.S.A. 77:4736–4740.

  17. 17.

    Chang, J., B. Lamb, L. Marinari, A. F. Kreft, andA. J. Lewis. 1985. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages.Eur. J. Pharmacol. 107:215–222.

  18. 18.

    Rouzer, C. A., W. A. Scott, Z. A. Cohn, P. Blackburn, andJ. A. Manning. 1980. Mouse peritoneal macrophages release leukotriene C in response to a phagocytic stimulus.Proc. Natl. Acad. Sci. U.S.A. 77:4928–4932.

  19. 19.

    Carlson, R. P., L. O'Neill-Davis, J. Chang, andA. J. Lewis. 1985. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents.Agents Actions 17:197–204.

  20. 20.

    Kazda, S., B. Garthoff, H. Meyer, K. Schlossmann, K. Stoepel, R. Towart, W. Vater, andE. Wehinger. 1980. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate (nisoldipine, Bay k 5552).Arzneim.-Forsch./Drug Res. 30:2144–2149.

  21. 21.

    Flower, R. J., andG. J. Blackwell. 1976. The importance of phospholipase A2 in prostaglandin biosynthesis.Biochem. Pharmacol. 25:285–291.

  22. 22.

    Ebel, V. S., H. Schutz, andA. Hornitschek. 1978. Untersuchungen zur Analytik von Nifedipin unter besonderer Berucksichtigung der bei Lichtexposition entstehenden Umwandlungsproduckte,Arzneim.-Forsch./Drug Res. 28:2188–2193.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chang, J., Blazek, E. & Carlson, R.P. Inhibition of phospholipase A2 (PLA2) activity by nifedipine and nisoldipine is independent of their calcium-channel-blocking activity. Inflammation 11, 353–364 (1987). https://doi.org/10.1007/BF00915839

Download citation

Keywords

  • PGE2
  • Nifedipine
  • Diltiazem
  • Calcium Antagonist
  • Felodipine